H.R. 8205
Reauthorizes Lou Gehrig's disease therapy programs
Extends through 2031 federal grants and a joint Food and Drug Administration-National Institutes of Health program for research on experimental treatments for Lou Gehrig's disease and other nerve diseases.
- Extends National Institutes of Health grants for experimental Lou Gehrig's disease drug research through 2031
- Extends Food and Drug Administration grants for therapies for Lou Gehrig's disease and other nerve diseases
- Keeps a joint Food and Drug Administration-National Institutes of Health partnership for treatment work
- Requires prompt reporting of serious unexpected side effects and a five-year plan
Became law · Public Law 119-138